BGLC
BioNexus Gene Lab Corp.
Price Chart
Latest Quote
$2.52
-0.08 (-3.08%)
Current Price
| Previous Close | $2.60 |
| Open | $2.49 |
| Day High | $2.60 |
| Day Low | $2.35 |
| Volume | 15,744 |
Stock Information
| Shares Outstanding | 2.42M |
| Total Debt | $347K |
| Cash Equivalents | $3.96M |
| Revenue | $5.31M |
| Net Income | $-2.90M |
| Sector | Basic Materials |
| Industry | Specialty Chemicals |
| Market Cap | $6.09M |
| EPS (TTM) | $-1.49 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.67M |
| Sales | $5.31M |
| Income | $-2.90M |
| Book/sh | $3.35 |
| Cash/sh | $1.64 |
| Employees | 19 |
Financial Ratios
| Quick Ratio | 5.27 |
| Current Ratio | 6.52 |
| Debt/Eq | 4.28 |
Returns & Margins
| ROA | -20.76% |
| ROE | -36.62% |
| Gross Margin | 13.95% |
| Operating Margin | -2466.01% |
| Profit Margin | -54.70% |
Ownership
| Insider Ownership | 35.59% |
| Institutional Ownership | 0.01% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 1.15 |
| P/B | 0.75 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $2.23 |
| SMA50 | $2.17 |
| SMA200 | $3.50 |
| RSI | 54.65 |
| ATR | 0.3221 |
| Shares Float | 1.76M |
| Short Float | 1.10% |
| Short Ratio | 0.81 |
| Volatility | 2.19 |
| Rel Volume | 0.05 |
Performance History
| Week | +27.92% |
| Month | +20.57% |
| Quarter | +0.24% |
| 6 Months | -39.13% |
| YTD | -36.04% |
| Year | -15.01% |
| 3 Years | -92.42% |
| 5 Years | -98.02% |
| 10 Years | -99.05% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $2.52 | 15,800 |
| 2026-06-16 | $2.60 | 17,100 |
| 2026-06-15 | $2.50 | 124,200 |
| 2026-06-12 | $2.14 | 155,700 |
| 2026-06-11 | $2.11 | 112,600 |
| 2026-06-10 | $1.97 | 4,804,500 |
| 2026-06-09 | $2.17 | 10,300 |
| 2026-06-08 | $2.19 | 1,200 |
| 2026-06-05 | $2.20 | 5,400 |
| 2026-06-04 | $2.30 | 1,200 |
| 2026-06-03 | $2.28 | 2,600 |
| 2026-06-02 | $2.30 | 6,000 |
| 2026-06-01 | $2.24 | 9,900 |
| 2026-05-29 | $2.32 | 213,500 |
| 2026-05-28 | $2.40 | 16,800 |
| 2026-05-27 | $2.22 | 251,300 |
| 2026-05-26 | $2.07 | 38,300 |
| 2026-05-22 | $2.02 | 1,900 |
| 2026-05-21 | $2.02 | 3,300 |
| 2026-05-20 | $2.09 | 1,700 |
| 2026-05-19 | $2.10 | 8,500 |
| 2026-05-18 | $2.09 | 11,400 |
About BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $6,339,694 | $8,221,125 | $8,441,308 | $9,669,678 |
| Cost Of Revenue | $6,339,694 | $8,221,125 | $8,441,308 | $9,669,678 |
| Total Revenue | $7,424,911 | $9,510,646 | $9,770,806 | $10,928,707 |
| Operating Revenue | $7,424,911 | $9,510,646 | $9,770,806 | $10,928,707 |
| Expenses | ||||
| Interest Expense | $19,542 | $21,146 | $13,929 | $12,479 |
| Total Expenses | $10,583,361 | $11,467,409 | $12,850,430 | $11,219,884 |
| Other Income Expense | $109,497 | $235,420 | $417,361 | - |
| Other Non Operating Income Expenses | $59,485 | $59,405 | $42,093 | - |
| Net Non Operating Interest Income Expense | $64,346 | $126,495 | $54,746 | $-12,479 |
| Interest Expense Non Operating | $19,542 | $21,146 | $13,929 | $12,479 |
| Operating Expense | $4,243,667 | $3,246,284 | $4,409,122 | $1,550,206 |
| Selling And Marketing Expense | $1,736,331 | $2,030,684 | $596,858 | - |
| General And Administrative Expense | $2,330,222 | $1,973,968 | $2,442,855 | $1,729,489 |
| Other Operating Expenses | - | - | $-486,036 | $-179,283 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-2,984,607 | $-1,598,342 | $-2,629,043 | $-355,966 |
| Net Interest Income | $64,346 | $126,495 | $54,746 | $-12,479 |
| Interest Income | $83,888 | $147,641 | $68,675 | - |
| Normalized Income | $-3,034,619 | $-1,732,113 | $-2,914,247 | $-355,966 |
| Net Income From Continuing And Discontinued Operation | $-2,984,607 | $-1,598,342 | $-2,629,043 | $-355,966 |
| Total Operating Income As Reported | $-2,965,065 | $-1,573,702 | $-2,593,588 | $-291,177 |
| Net Income Common Stockholders | $-2,984,607 | $-1,598,342 | $-2,629,043 | $-355,966 |
| Net Income | $-2,984,607 | $-1,598,342 | $-2,629,043 | $-355,966 |
| Net Income Including Noncontrolling Interests | $-2,984,607 | $-1,598,342 | $-2,629,043 | $-355,966 |
| Net Income Continuous Operations | $-2,984,607 | $-1,598,342 | $-2,629,043 | $-355,966 |
| Pretax Income | $-2,984,607 | $-1,594,848 | $-2,607,517 | $-303,656 |
| Interest Income Non Operating | $83,888 | $147,641 | $68,675 | - |
| Operating Income | $-3,158,450 | $-1,956,763 | $-3,079,624 | $-291,177 |
| Gross Profit | $1,085,217 | $1,289,521 | $1,329,498 | $1,259,029 |
| Per Share | ||||
| Diluted EPS | $-1.61 | $-0.90 | $-1.66 | $-0.46 |
| Basic EPS | $-1.61 | $-0.90 | $-1.66 | $-0.46 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $42,244 | $90,064 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-2,846,770 | $-1,596,574 | $-2,860,433 | $-185,758 |
| Total Unusual Items | $50,012 | $176,015 | $375,268 | - |
| Total Unusual Items Excluding Goodwill | $50,012 | $176,015 | $375,268 | - |
| Reconciled Depreciation | $168,307 | $153,143 | $108,423 | $105,419 |
| EBITDA (Bullshit earnings) | $-2,796,758 | $-1,420,559 | $-2,485,165 | $-185,758 |
| EBIT | $-2,965,065 | $-1,573,702 | $-2,593,588 | $-291,177 |
| Diluted Average Shares | $1,856,680 | $1,781,848 | $1,587,545 | $1,440,973 |
| Basic Average Shares | $1,856,680 | $1,781,848 | $1,587,545 | $1,440,973 |
| Diluted NI Availto Com Stockholders | $-2,984,607 | $-1,598,342 | $-2,629,043 | $-355,966 |
| Tax Provision | $0 | $3,494 | $21,526 | $52,310 |
| Gain On Sale Of Security | $50,012 | $176,015 | $375,268 | - |
| Provision For Doubtful Accounts | $126,444 | $-805,879 | $1,314,427 | - |
| Research And Development | $50,670 | $47,511 | $54,982 | - |
| Selling General And Administration | $4,066,553 | $4,004,652 | $3,039,713 | $1,729,489 |
| Other Gand A | $1,535,452 | $1,832,968 | $2,442,855 | $1,729,489 |
| Salaries And Wages | $794,770 | $141,000 | - | - |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $8,614,928 | $8,322,804 | $9,657,852 | $6,665,013 |
| Total Assets | $9,252,784 | $10,433,848 | $11,399,793 | $8,740,162 |
| Total Non Current Assets | $3,804,046 | $3,003,399 | $3,352,993 | $2,718,336 |
| Current Assets | $5,448,738 | $7,430,449 | $8,046,800 | $6,021,826 |
| Other Current Assets | $83,333 | - | - | - |
| Inventory | $676,703 | $1,388,624 | $1,137,770 | $977,807 |
| Receivables | $648,997 | $1,664,398 | $979,694 | $2,925,155 |
| Other Receivables | $81,728 | $203,660 | $122,432 | $25,240 |
| Taxes Receivable | $61,384 | $84,167 | $57,588 | $31,551 |
| Accounts Receivable | $505,885 | $1,376,571 | $799,674 | $2,868,364 |
| Allowance For Doubtful Accounts Receivable | $-703,995 | $-517,877 | $-1,307,508 | $-12,600 |
| Gross Accounts Receivable | $1,209,880 | $1,894,448 | $2,107,182 | $2,868,364 |
| Cash Cash Equivalents And Short Term Investments | $4,039,705 | $4,377,427 | $5,929,336 | $2,118,864 |
| Cash And Cash Equivalents | $4,039,705 | $4,377,427 | $5,929,336 | $2,118,864 |
| Cash Equivalents | $1,656,336 | $2,793,948 | $3,305,371 | $1,507,015 |
| Cash Financial | $2,383,369 | $1,583,479 | $2,623,965 | $611,849 |
| Current Deferred Assets | - | - | - | $0 |
| Debt | ||||
| Total Debt | $176,046 | $210,557 | $133,395 | $56,775 |
| Long Term Debt And Capital Lease Obligation | $116,899 | $159,741 | $98,763 | $40,206 |
| Current Debt And Capital Lease Obligation | $59,147 | $50,816 | $34,632 | $16,569 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $637,856 | $2,111,044 | $1,741,941 | $2,075,149 |
| Total Non Current Liabilities Net Minority Interest | $116,899 | $159,741 | $111,018 | $71,072 |
| Current Liabilities | $520,957 | $1,951,303 | $1,630,923 | $2,004,077 |
| Current Deferred Liabilities | $8,385 | $95,879 | $0 | $23,123 |
| Payables And Accrued Expenses | $453,425 | $1,804,608 | $1,596,291 | $1,964,385 |
| Payables | $453,425 | $1,804,608 | $1,596,291 | $1,964,385 |
| Other Payable | $401,611 | $284,108 | $180,912 | $103,370 |
| Accounts Payable | $2,335 | $1,503,326 | $1,402,180 | $1,861,015 |
| Non Current Deferred Liabilities | - | $0 | $12,255 | $30,866 |
| Non Current Deferred Taxes Liabilities | - | $0 | $12,255 | $30,866 |
| Total Tax Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $8,614,928 | $8,322,804 | $9,657,852 | $6,665,013 |
| Total Equity Gross Minority Interest | $8,614,928 | $8,322,804 | $9,657,852 | $6,665,013 |
| Stockholders Equity | $8,614,928 | $8,322,804 | $9,657,852 | $6,665,013 |
| Gains Losses Not Affecting Retained Earnings | $-120,749 | $-555,000 | $-677,294 | $-409,062 |
| Other Equity Adjustments | $-120,749 | $-555,000 | $-677,294 | $-409,062 |
| Retained Earnings | $-6,427,227 | $-3,442,620 | $-1,844,278 | $1,156,392 |
| Other | ||||
| Ordinary Shares Number | $2,417,314 | $1,796,766 | $1,766,766 | $1,447,651 |
| Share Issued | $2,417,314 | $1,796,766 | $1,766,766 | $1,447,651 |
| Tangible Book Value | $8,614,928 | $8,322,804 | $9,657,852 | $6,665,013 |
| Invested Capital | $8,614,928 | $8,322,804 | $9,657,852 | $6,665,013 |
| Working Capital | $4,927,781 | $5,479,146 | $6,415,877 | $4,017,749 |
| Capital Lease Obligations | $176,046 | $210,557 | $133,395 | $56,775 |
| Total Capitalization | $8,614,928 | $8,322,804 | $9,657,852 | $6,665,013 |
| Additional Paid In Capital | $-5,011,891 | $-5,011,891 | $-5,011,891 | $-5,011,891 |
| Capital Stock | $20,174,795 | $17,332,315 | $17,191,315 | $10,929,574 |
| Common Stock | $20,174,795 | $17,332,315 | $17,191,315 | $10,929,574 |
| Long Term Capital Lease Obligation | $116,899 | $159,741 | $98,763 | $40,206 |
| Current Deferred Revenue | $8,385 | $95,879 | $0 | $23,123 |
| Current Capital Lease Obligation | $59,147 | $50,816 | $34,632 | $16,569 |
| Dueto Related Parties Current | $49,479 | $17,174 | $13,199 | $0 |
| Investments And Advances | $2,027,540 | $1,265,166 | $1,699,831 | $1,150,898 |
| Other Investments | $2,027,540 | $1,265,166 | $1,699,831 | $1,150,898 |
| Net PPE | $1,776,506 | $1,738,233 | $1,653,162 | $1,567,438 |
| Accumulated Depreciation | $-909,022 | $-797,149 | $-659,115 | $-616,913 |
| Gross PPE | $2,685,528 | $2,535,382 | $2,312,277 | $2,184,351 |
| Other Properties | $658,260 | $534,557 | $396,696 | $411,617 |
| Machinery Furniture Equipment | $520,299 | $493,856 | $299,103 | $265,765 |
| Properties | $1,506,969 | $1,506,969 | $1,506,969 | $1,506,969 |
| Finished Goods | $676,703 | $1,388,624 | $1,137,770 | $977,807 |
| Construction In Progress | - | $0 | $109,509 | $0 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-1,875,353 | $-2,320,249 | $-1,971,610 | $497,651 |
| Operating Activities | ||||
| Operating Cash Flow | $-1,838,382 | $-2,093,260 | $-1,822,212 | $551,822 |
| Cash Flow From Continuing Operating Activities | $-1,838,382 | $-2,093,260 | $-1,822,212 | $551,822 |
| Operating Gains Losses | $-49,313 | $-106,539 | $-68,654 | $-115,379 |
| Investing Activities | ||||
| Capital Expenditure | $-36,971 | $-226,989 | $-149,398 | $-54,171 |
| Investing Cash Flow | $944,751 | $418,202 | $-1,794,202 | $-450,498 |
| Cash Flow From Continuing Investing Activities | $944,751 | $418,202 | $-1,794,202 | $-450,498 |
| Net Other Investing Changes | - | $79,851 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $267,311 | $0 | - | $150,000 |
| Financing Cash Flow | $298,841 | $3,975 | $6,274,939 | $108,168 |
| Cash Flow From Continuing Financing Activities | $298,841 | $3,975 | $6,274,939 | $108,168 |
| Net Other Financing Charges | $31,530 | $3,975 | $6,274,939 | $150,000 |
| Net Common Stock Issuance | $267,311 | $0 | - | $150,000 |
| Common Stock Issuance | $267,311 | $0 | - | $150,000 |
| Dividends Received Cfi | $22,112 | $68,130 | $61,409 | $115,379 |
| Cash Dividends Paid | - | - | $0 | $0 |
| Other | ||||
| Interest Paid Supplemental Data | $6,865 | $9,351 | $8,877 | $12,479 |
| Income Tax Paid Supplemental Data | $14,823 | $40,380 | $66,973 | $170,447 |
| End Cash Position | $2,486,383 | $2,886,966 | $4,517,710 | $2,118,864 |
| Beginning Cash Position | $2,886,966 | $4,517,710 | $2,118,864 | $2,123,919 |
| Effect Of Exchange Rate Changes | $194,207 | $40,339 | $-259,679 | $-214,547 |
| Changes In Cash | $-594,790 | $-1,671,083 | $2,658,525 | $209,492 |
| Net Investment Purchase And Sale | $959,610 | $497,210 | $-1,706,213 | $-511,706 |
| Sale Of Investment | $1,031,629 | $1,068,777 | $26,146 | $0 |
| Purchase Of Investment | $-72,019 | $-571,567 | $-1,732,359 | $-511,706 |
| Net PPE Purchase And Sale | $-36,971 | $-226,989 | $-149,398 | $-54,171 |
| Purchase Of PPE | $-36,971 | $-226,989 | $-149,398 | $-54,171 |
| Change In Working Capital | $12,052 | $115,398 | $117,979 | $833,385 |
| Change In Other Working Capital | $-64,711 | $57,045 | $-67,771 | $-2,988 |
| Change In Other Current Liabilities | $-34,511 | $-42,895 | $76,620 | $-126,686 |
| Change In Payables And Accrued Expense | $-1,383,488 | $204,342 | $-381,293 | $-119,695 |
| Change In Payable | $-1,383,488 | $204,342 | $-381,293 | $-119,695 |
| Change In Inventory | $711,921 | $-250,854 | $-160,387 | $544,108 |
| Change In Receivables | $782,841 | $147,760 | $650,810 | $538,646 |
| Stock Based Compensation | $794,770 | $141,000 | $511,740 | $0 |
| Unrealized Gain Loss On Investment Securities | $93,965 | $-69,476 | $-306,614 | $70,628 |
| Provisionand Write Offof Assets | $126,444 | $-805,879 | $942,800 | $0 |
| Asset Impairment Charge | $0 | $46,517 | $12,897 | $5,941 |
| Depreciation Amortization Depletion | $168,307 | $153,143 | $108,423 | $105,419 |
| Depreciation And Amortization | $168,307 | $153,143 | $108,423 | $105,419 |
| Depreciation | $168,307 | $153,143 | $108,423 | $105,419 |
| Gain Loss On Investment Securities | $-49,313 | $-106,539 | $-68,654 | $-115,379 |
| Net Income From Continuing Operations | $-2,984,607 | $-1,598,342 | $-2,629,043 | $-355,966 |
| Other Non Cash Items | - | $30,918 | $8,877 | $7,794 |
| Repayment Of Debt | - | - | $0 | $-34,038 |
| Interest Paid Cff | - | - | $-8,877 | $-7,794 |
| Net Issuance Payments Of Debt | - | - | $0 | $-34,038 |
| Net Long Term Debt Issuance | - | - | $0 | $-34,038 |
| Long Term Debt Payments | - | - | $0 | $-34,038 |
| Changes In Account Receivables | - | - | $650,810 | $538,646 |
| Net Business Purchase And Sale | - | - | - | - |
| Sale Of Business | - | - | - | - |
| Sale Of PPE | - | - | - | - |
| Gain Loss On Sale Of PPE | - | - | - | - |
Fetched: 2026-06-15